Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH), mehr …
www.guetsel.de/content/38647/novo-nordisk-expands-research-collaboration-in-novel-delivery-technologies-for-biologic-medicines.html
GB Sciences Signs Licensing Deal With «EndoPure« Life Sciences for 5 Percent Gross Sales Royalty & Sponsorship of First in Human Trial for Their Cannabinoid Based Parkinson’s Drug
As a part of their Exclusive Licensing Deal, “EndoPure” Life Sciences will finance and sponsor first in human clinical trials, which help to advance GB Sciences’ cannabinoid based products globally, mehr …
www.guetsel.de/content/94248/gb-sciences-signs-licensing-deal-with-endopure-life-sciences-for-5-percent-gross-sales-royalty-und-sponsorship-of-first-in-human-trial-for-their-cannabinoid-based-parkinsons-drug.html
Bäckerhefe Saccharomyces cerevisiae ist Mikrobe des Jahres 2022
Wenn zu Jahresbeginn die Sektkorken knallen, ist die Mikrobe des Jahres 2022 beteiligt: Die Bäckerhefe Saccharomyces cerevisiae produziert neben Wein – der Grundlage von Sekt – und Bier auch Kuchen und Brot, mehr …
www.guetsel.de/content/33645/baeckerhefe-saccharomyces-cerevisiae-ist-mikrobe-des-jahres-2022.html
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding, mehr …
www.guetsel.de/content/41695/heavy-bleeding-after-giving-birth-is-globally-a-leading-cause-of-death-in-new-mothers.html
Novo Nordisk to Expand R & D Presence in Greater Boston Area
Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark, mehr …
www.guetsel.de/content/60535/novo-nordisk-to-expand-r-und-d-presence-in-greater-boston-area.html
Pharming: Joenja (Leniolisib) von der FDA als erste und einzige Behandlung für APDS zugelassen
APDS (aktivierte Phosphoinositid 3 Kinase delta (PI3Kδ) Syndrom) ist eine seltene und fortschreitende primäre Immundefizienz, mehr …
www.guetsel.de/content/62532/pharming-joenja-leniolisib-von-der-fda-als-erste-und-einzige-behandlung-fuer-apds-zugelassen.html
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with Kathy Ireland
Tune in this Sunday, December 17th, 2023, at 5.30 p. m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid based medicine for the treatment of Parkinson’s disease, mehr …
www.guetsel.de/content/80393/gb-sciences-novel-parkinsons-disease-medication-is-featured-on-worldwide-business-with-kathy-ireland.html
Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia
Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U. S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for BNT200, mehr …
www.guetsel.de/content/34124/blue-note-therapeutics-receives-breakthrough-device-designation-for-prescription-only-digital-therapeutic-for-myeloid-leukemia.html
Medico International – Aktionswoche für Patentfreigabe in Berlin: Bundesregierung muss Blockadehaltung aufgeben
Anlässlich der bevorstehenden Sitzung des TRIPS Council bei der Welthandelsorganisation (WTO) organisiert das Bündnis »Make them Sign!« eine Aktionswoche in Berlin. Die Protestwoche startet mit einer Fotoaktionen am morgigen Dienstag um 12 Uhr vor dem Bundeskanzleramt. Am kommenden Sonntag beteiligt sich das Bündnis dann an einer Demonstration, die, mehr …
www.guetsel.de/content/22793/medico-international-aktionswoche-fuer-patentfreigabe-in-berlin-bundesregierung-muss-blockadehaltung-aufgeben.html
Novo Nordisk A/S, Share repurchase programme
On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
www.guetsel.de/content/34308/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk A/S, Share repurchase programme
This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021, mehr …
www.guetsel.de/content/34754/novo-nordisk-a-s-share-repurchase-programme.html
Dr. David Margulies and Dr. Hal C. Lewis Present Healing and Regenerating the Injured Brain
Recent advances in biomolecular medicine and biotechnology will make it possible for the injured brain to regenerate, mehr …
www.guetsel.de/content/34992/dr-david-margulies-and-dr-hal-c-lewis-present-healing-and-regenerating-the-injured-brain.html
Jemen: Oxfam fordert von UN Sicherheitsrat neue Anstrengungen für Friedensgespräche
Oxfam fordert den UN Sicherheitsrat auf, die jüngsten Angriffe im Jemen zu verurteilen und neue Anstrengungen für Friedensgesprächen zu unternehmen, um den seit sieben Jahren andauernden Konflikt zu beenden, mehr …
www.guetsel.de/content/35449/jemen-oxfam-fordert-von-un-sicherheitsrat-neue-anstrengungen-fuer-friedensgespraeche.html
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse, mehr …
www.guetsel.de/content/36257/novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons.html
Novavax gibt positive Ergebnisse des Impfstoffes Covid 19 in der pädiatrischen Population der klinischen Phase 3 Studie »Prevent 19« bekannt
»Prevent 19« pädiatrische Erweiterung bei Jugendlichen im Alter von 12 bis 17 Jahren erreicht primären Wirksamkeitsendpunkt, der die Vergleichbarkeit mit der Erwachsenenpopulation belegt, mehr …
www.guetsel.de/content/36713/novavax-gibt-positive-ergebnisse-des-impfstoffes-covid-19-in-der-paediatrischen-population-der-klinischen-phase-3-studie-prevent-19-bekannt.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
www.guetsel.de/content/36829/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk A/S: Share repurchase programme
On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
www.guetsel.de/content/37458/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
www.guetsel.de/content/39024/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk A/S, Share Repurchase Programme
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
www.guetsel.de/content/43106/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials
Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec, mehr …
www.guetsel.de/content/44467/novo-nordisk-achieves-primary-objectives-of-onwards-1-and-6-trials.html
Novo Nordisk—major shareholder announcement
Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
www.guetsel.de/content/44672/novo-nordisk-major-shareholder-announcement.html
Hope for leukaemia patients through discovery at Karolinska University Hospital
In a recently published study, Nikolas Herold and Martin Jädersten from Karolinska University Hospital show how acute myeloid leukaemia can be treated more effectively. They have reused an already proven medicinal product, mehr …
www.guetsel.de/content/49090/hope-for-leukaemia-patients-through-discovery-at-karolinska-university-hospital.html
Once-weekly insulin icodec demonstrates superior reduction in HbA1c
Mehr …
p style="line-height:150%;">www.guetsel.de/content/51554/once-weekly-insulin-icodec-demonstrates-superior-reduction-in-hba1c.html
Novo Nordisk A/S, Share repurchase programme
The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues, mehr …
www.guetsel.de/content/53353/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities, mehr …
www.guetsel.de/content/54158/novo-nordisk-invests-dkk-5-4-bn-danish-kroner-in-expansion-of-clinical-manufacturing-facilities-in-bagsv-aelig-rd-denmark.html
